Yitian Zhou

JSON
CSV
XLSX
TXT

Primary: Shown in the list of current labels.

Year 2026

PubMed DOI Crossref
Association between CYP2D6 and CYP2C19 genotypes and venlafaxine treatment failure: a retrospective study on two cohorts from Norway and the UK
Park Y, Lenk HÇ, Zhou Y, Lauschke VM, Molden E
The Lancet Psychiatry 13 (10) 852-860 [2026-10-00; online 2026-10-00]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real-World Setting.
Park Y, Zhou Y, Lauschke VM
Clin. Pharmacol. Ther. 120 (2) 412-419 [2026-08-00; online 2026-04-14]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Prediction of drug hypersensitivity by comprehensive modeling of HLA-peptidomes.
Zhong Y, Lauschke VM, Wang Y, Zhou Y
Brief. Bioinformatics 27 (4) - [2026-07-03; online 2026-07-03]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Feed-Forward Deep Neural Networks Predict Substrate-Specific Effects of Transporter Variants to Explain Drug Response Variability.
Park Y, Zhou Y, Xiao M, Nies AT, Lauschke VM
Clin Transl Sci 19 (5) e70592 [2026-05-00; online 2026-05-09]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Comprehensive overview of the global pharmacogenetic and functional variability in NUDT15.
Zhou Y, Lauschke LM, Lauschke VM
Hum Genomics 20 (1) - [2026-04-04; online 2026-04-04]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Substrate-specificity of pharmacogenomic variability - clinical relevance and emerging predictive strategies.
Zhou Y, Park Y, Lauschke VM
Expert Opin Drug Metab Toxicol 22 (3) 201-215 [2026-03-00; online 2026-04-02]
DDLS Fellow Yitian Zhou

Year 2025

PubMed DOI Crossref
Integration of germline pharmacogenomic burden to predict fluoropyrimidine-related toxicity - A secondary analysis of the PREPARE trial.
De Mattia E, Park Y, Peruzzi E, ..., Lauschke VM, Cecchin E
Oncogene 44 (45) 4352-4362 [2025-11-00; online 2025-09-25]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Opportunities and Challenges of Population Pharmacogenomics.
Zhou Y, Park Y, Camara MD, Lauschke VM
Ann Hum Genet 89 (5) 384-397 [2025-09-00; online 2025-04-02]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Improved Prediction of CYP2D6 Catalyzed Drug Metabolism by Taking Variant Substrate Specificities and Novel Polymorphic Haplotypes into Account.
Johansson I, Xanthopoulou EM, Zhou Y, ..., Jukic MM, Ingelman-Sundberg M
Clin. Pharmacol. Ther. 118 (1) 218-231 [2025-07-00; online 2025-04-22]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes.
Johansson I, Lu Y, Zhou Y, ..., Milani L, Ingelman-Sundberg M
Hum Genomics 19 (1) 62 [2025-05-28; online 2025-05-28]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Machine learning models for pharmacogenomic variant effect predictions - recent developments and future frontiers.
Tremmel R, Honore A, Park Y, ..., Xiao M, Lauschke VM
Pharmacogenomics 26 (5-6) 171-182 [2025-05-22; online 2025-05-22]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Evaluating the synergistic use of advanced liver models and AI for the prediction of drug-induced liver injury.
Zhou Y, Zhong Y, Lauschke VM
Expert Opin Drug Metab Toxicol 21 (5) 563-577 [2025-05-00; online 2025-02-02]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Translating pharmacogenomic sequencing data into drug response predictions-How to interpret variants of unknown significance.
Tremmel R, Pirmann S, Zhou Y, Lauschke VM
Br J Clin Pharmacol 91 (2) 252-263 [2025-02-00; online 2023-10-16]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Molecular docking to investigate HLA-associated idiosyncratic drug reactions.
Li K, Lauschke VM, Zhou Y
Drug Metab Rev 57 (1) 67-90 [2025-02-00; online 2025-01-20]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
PharmFreq: a comprehensive atlas of ethnogeographic allelic variation in clinically important pharmacogenes.
Tremmel R, Zhou Y, Camara MD, ..., Eliasson E, Lauschke VM
Nucleic Acids Res. 53 (D1) D1498-D1509 [2025-01-06; online 2024-11-14]
DDLS Fellow Yitian Zhou

Year 2024

PubMed DOI Crossref
Population-scale variability of the human UDP-glycosyltransferase gene family.
González-Padilla D, Camara MD, Lauschke VM, Zhou Y
J Genet Genomics 51 (11) 1228-1236 [2024-11-00; online 2024-07-04]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y, Pirmann S, Lauschke VM
Pharmacogenomics J. 24 (3) 17 [2024-05-27; online 2024-05-27]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Population-specific variations in KCNH2 predispose patients to delayed ventricular repolarization upon dihydroartemisinin-piperaquine therapy.
Camara MD, Zhou Y, Dara A, ..., Gil PJ, Lauschke VM
Antimicrob. Agents Chemother. 68 (5) e0139023 [2024-05-02; online 2024-03-28]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Meta-analysis of the global distribution of clinically relevant CYP2C8 alleles and their inferred functional consequences.
Camara MD, Zhou Y, De Sousa TN, ..., Djimde AA, Lauschke VM
Hum Genomics 18 (1) 40 [2024-04-22; online 2024-04-22]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Next-generation sequencing in pharmacogenomics - fit for clinical decision support?
Zhou Y, Lauschke VM
Expert Rev Clin Pharmacol 17 (3) 213-223 [2024-03-00; online 2024-01-23]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Pharmacogenomics Beyond Single Common Genetic Variants: The Way Forward.
Lauschke VM, Zhou Y, Ingelman-Sundberg M
Annu Rev Pharmacol Toxicol 64 (-) 33-51 [2024-01-23; online 2023-07-28]
DDLS Fellow Yitian Zhou

Year 2023

PubMed DOI Crossref
Structural variation of the coding and non-coding human pharmacogenome.
Tremmel R, Zhou Y, Schwab M, Lauschke VM
NPJ Genom Med 8 (1) 24 [2023-09-08; online 2023-09-08]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Cross-Ancestry Genome-Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations.
Khor CC, Winter S, Sutiman N, ..., Chowbay B, Schroth W
Clin. Pharmacol. Ther. 113 (3) 712-723 [2023-03-00; online 2023-01-31]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences.
Zhou Y, Nevosadová L, Eliasson E, Lauschke VM
Hum Genomics 17 (1) 15 [2023-02-28; online 2023-02-28]
DDLS Fellow Yitian Zhou

Year 2022

PubMed DOI Crossref
Scellseg: A style-aware deep learning tool for adaptive cell instance segmentation by contrastive fine-tuning.
Xun D, Chen D, Zhou Y, ..., Wang R, Wang Y
iScience 25 (12) 105506 [2022-12-22; online 2022-11-04]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y, Lauschke VM
Pharmacogenomics J. 22 (5-6) 284-293 [2022-12-00; online 2022-09-06]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Should we test for SLCO1B1 genotype before prescribing statins?-a discussion of clinical trial results.
Zhou Y, Lauschke VM
Ann Transl Med 10 (23) 1293 [2022-12-00; online 2023-01-10]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
A paradigm shift in pharmacogenomics: From candidate polymorphisms to comprehensive sequencing.
Zhou Y, Koutsilieri S, Eliasson E, Lauschke VM
Basic Clin. Pharmacol. Toxicol. 131 (6) 452-464 [2022-12-00; online 2022-08-22]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk.
De Mattia E, Silvestri M, Polesel J, ..., Toffoli G, Cecchin E
Biomed. Pharmacother. 154 (-) 113644 [2022-10-00; online 2022-09-02]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Challenges and opportunities associated with rare-variant pharmacogenomics.
Zhou Y, Tremmel R, Schaeffeler E, Schwab M, Lauschke VM
Trends Pharmacol. Sci. 43 (10) 852-865 [2022-10-00; online 2022-08-22]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Challenges Related to the Use of Next-Generation Sequencing for the Optimization of Drug Therapy.
Zhou Y, Lauschke VM
Handb Exp Pharmacol 280 (-) 237-260 [2022-07-07; online 2022-07-07]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health.
Zhou Y, Lauschke VM
Hum. Genet. 141 (6) 1113-1136 [2022-06-00; online 2021-10-15]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Genetic Variant ABCC1 rs45511401 Is Associated with Increased Response to Statins in Patients with Familial Hypercholesterolemia.
Dagli-Hernandez C, Borges JB, Marçal EDSR, ..., Hirata MH, Hirata RDC
Pharmaceutics 14 (5) - [2022-04-27; online 2022-04-27]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts.
Dagli-Hernandez C, Zhou Y, Lauschke VM, ..., Hirata MH, Hirata RDC
Pharmacol Rep 74 (1) 47-66 [2022-02-00; online 2021-08-17]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Identification and functional validation of novel pharmacogenomic variants using a next-generation sequencing-based approach for clinical pharmacogenomics.
Siamoglou S, Koromina M, Hishinuma E, ..., Hiratsuka M, Patrinos GP
Pharmacol Res 176 (-) 106087 [2022-02-00; online 2022-01-13]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development-Current State-of-the-Art and Future Perspectives.
Youhanna S, Kemas AM, Preiss L, ..., Sellgren CM, Lauschke VM
Pharmacol Rev 74 (1) 141-206 [2022-01-00; online 2022-01-13]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Novel loss-of-function variant in DENND5A impedes melanosomal cargo transport and predisposes to familial cutaneous melanoma.
Yang M, Johnsson P, Bräutigam L, ..., Cao Y, Höiom V
Genet Med 24 (1) 157-169 [2022-01-00; online 2021-11-30]
DDLS Fellow Yitian Zhou

Year 2021

PubMed DOI Crossref
Pharmacogenomics of Antihypertensive Drugs in Brazil: Recent Progress and Clinical Implications.
Vecchia Genvigir FD, Dagli-Hernandez C, Hirata TDC, ..., Hirata MH, Hirata RDC
Endocr Metab Immune Disord Drug Targets 22 (13) 1263-1275 [2021-12-25; online 2021-12-25]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.
Hirata TDC, Dagli-Hernandez C, Genvigir FDV, ..., Hirata MH, Hirata RDC
Mol Diagn Ther 25 (6) 735-755 [2021-11-00; online 2021-08-06]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine.
Zhou Y, Arribas GH, Turku A, ..., Gastaldello S, Lauschke VM
Sci Adv 7 (36) eabi6856 [2021-09-03; online 2021-09-01]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Computational Tools to Assess the Functional Consequences of Rare and Noncoding Pharmacogenetic Variability.
Zhou Y, Lauschke VM
Clin. Pharmacol. Ther. 110 (3) 626-636 [2021-09-00; online 2021-06-10]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Editorial: Population Pharmacogenomics (PGx): From Variant Identification to Clinical Implementation.
Hiratsuka M, Zhou Y, Lauschke VM
Front Genet 12 (-) 736626 [2021-08-05; online 2021-08-05]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes.
Wang T, Zhou Y, Cao G
European journal of clinical pharmacology 77 (8) 1095-1111 [2021-08-00; online 2021-01-29]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Pharmacogenomics in the era of next generation sequencing - from byte to bedside.
Russell LE, Zhou Y, Almousa AA, ..., Nwabufo CK, Lauschke VM
Drug Metab Rev 53 (2) 253-278 [2021-05-00; online 2021-05-17]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Global Frequencies of Clinically Important HLA Alleles and Their Implications For the Cost-Effectiveness of Preemptive Pharmacogenetic Testing.
Zhou Y, Krebs K, Milani L, Lauschke VM
Clin. Pharmacol. Ther. 109 (1) 160-174 [2021-01-00; online 2020-07-26]
DDLS Fellow Yitian Zhou

Year 2020

PubMed DOI Crossref
Population-scale predictions of DPD and TPMT phenotypes using a quantitative pharmacogene-specific ensemble classifier.
Zhou Y, Dagli Hernandez C, Lauschke VM
Br. J. Cancer 123 (12) 1782-1789 [2020-12-00; online 2020-09-25]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Impact of variants in ATP-binding cassette transporters on breast cancer treatment.
Xiao Q, Zhou Y, Lauschke VM
Pharmacogenomics 21 (18) 1299-1310 [2020-12-00; online 2020-11-23]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients.
Xiao Q, Zhou Y, Winter S, ..., Schwab M, Lauschke VM
Int. J. Cancer 146 (9) 2475-2487 [2020-05-01; online 2020-02-17]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Ethnogeographic and inter-individual variability of human ABC transporters.
Xiao Q, Zhou Y, Lauschke VM
Hum. Genet. 139 (5) 623-646 [2020-05-00; online 2020-03-23]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
In Vitro Functional Characterization and in Silico Prediction of Rare Genetic Variation in the Bile Acid and Drug Transporter, Na+-Taurocholate Cotransporting Polypeptide (NTCP, SLC10A1).
Russell LE, Zhou Y, Lauschke VM, Kim RB
Mol. Pharm. 17 (4) 1170-1181 [2020-04-06; online 2020-03-10]
DDLS Fellow Yitian Zhou

Year 2019

PubMed DOI Crossref
Pharmacogenomic network analysis of the gene-drug interaction landscape underlying drug disposition.
Zhou Y, Lauschke VM
Comput Struct Biotechnol J 18 (-) 52-58 [2019-12-05; online 2019-12-05]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinoma.
Lauschke VM, Nordling Å, Zhou Y, ..., Barragan I, Ingelman-Sundberg M
Pharmacogenomics 20 (15) 1085-1092 [2019-10-00; online 2019-10-08]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Comprehensive Evaluation of Organotypic and Microphysiological Liver Models for Prediction of Drug-Induced Liver Injury.
Zhou Y, Shen JX, Lauschke VM
Front. Pharmacol. 10 (-) 1093 [2019-09-24; online 2019-09-24]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives as Potent Cholinesterase Inhibitors.
Svobodova B, Mezeiova E, Hepnarova V, ..., Marco-Contelles J, Korabecny J
Biomolecules 9 (8) - [2019-08-19; online 2019-08-19]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.
Lauschke VM, Zhou Y, Ingelman-Sundberg M
Pharmacol Ther 197 (-) 122-152 [2019-05-00; online 2019-01-22]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y, Mkrtchian S, Kumondai M, Hiratsuka M, Lauschke VM
Pharmacogenomics J. 19 (2) 115-126 [2019-04-00; online 2018-09-12]
DDLS Fellow Yitian Zhou

Year 2018

PubMed DOI Crossref
Computational Methods for the Pharmacogenetic Interpretation of Next Generation Sequencing Data.
Zhou Y, Fujikura K, Mkrtchian S, Lauschke VM
Front. Pharmacol. 9 (-) 1437 [2018-12-04; online 2018-12-04]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk.
Zhou Y, Mägi R, Milani L, Lauschke VM
J. Lipid Res. 59 (10) 1987-2000 [2018-10-00; online 2018-08-03]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews.
Zhou Y, Lauschke VM
J. Med. Genet. 55 (9) 617-627 [2018-09-00; online 2018-07-03]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions.
Vorrink SU, Zhou Y, Ingelman-Sundberg M, Lauschke VM
Toxicol Sci 163 (2) 655-665 [2018-06-01; online 2018-03-29]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Integrating rare genetic variants into pharmacogenetic drug response predictions.
Ingelman-Sundberg M, Mkrtchian S, Zhou Y, Lauschke VM
Hum Genomics 12 (1) 26 [2018-05-25; online 2018-05-25]
DDLS Fellow Yitian Zhou

Year 2017

PubMed DOI Crossref
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y, Ingelman-Sundberg M, Lauschke VM
Clin. Pharmacol. Ther. 102 (4) 688-700 [2017-10-00; online 2017-05-26]
DDLS Fellow Yitian Zhou

Year 2014

PubMed DOI Crossref
Trend of telomerase activity change during human iPSC self-renewal and differentiation revealed by a quartz crystal microbalance based assay.
Zhou Y, Zhou P, Xin Y, ..., Wei S, Ma H
Sci Rep 4 (-) 6978 [2014-11-10; online 2014-11-10]
DDLS Fellow Yitian Zhou
PubMed DOI Crossref
Molecular composition, grafting density and film area affect the swelling-induced Au-S bond breakage.
Lv B, Zhou Y, Cha W, ..., Chi L, Ma H
ACS Appl Mater Interfaces 6 (11) 8313-8319 [2014-06-11; online 2014-05-20]
DDLS Fellow Yitian Zhou
SciLifeLab Data Centre
Publications 9.5.2